reSee.it - Related Video Feed

Myocarditis was found more in young men, with rates highest in those aged 16-17. The condition was less common in women and older age groups. Most cases were mild, but some were severe, impacting a person's life. Myocarditis was most common after the second vaccine dose and less frequent in younger children and with subsequent doses. Natural immunity from previous COVID infection was shown to be effective, even more so than two vaccine doses. Combining previous infection with vaccination provided even better protection. The speaker did not take a booster shot. Translation: Myocarditis was more common in young men, especially those aged 16-17. Most cases were mild, but some were severe. The condition was most frequent after the second vaccine dose. Natural immunity from prior COVID infection was found to be effective, even more so than two vaccine doses. Combining previous infection with vaccination provided even better protection. The speaker did not take a booster shot.

Today, the speaker discusses the transmission and viral load of vaccinated individuals compared to unvaccinated individuals. They mention the example of Israel, where a professor from Tel Aviv hospital stated that 75% of hospitalized patients were vaccinated. The speaker argues against the narrative that vaccinated individuals are solely responsible for immunity. They emphasize that the disease has a low mortality rate and question the need for continued booster shots. The other speaker counters by stating that vaccines protect against severe forms of the virus, particularly for those under 60 years old. The conversation ends with a disagreement about the percentage of vaccinated individuals in hospitals.

Myocarditis was most common in young men, with rates as high as 1 in 5000 vaccine recipients. The condition was mostly mild but could have lasting effects. Natural immunity from prior COVID infection was shown to be more protective than two vaccine doses. Combining prior infection with vaccination provided even better protection. The speaker did not take a booster shot.

A recent CDC study involving 10,000 participants shows that those who received a third booster shot had significantly more antibodies and better protection compared to those who did not. As we approach the winter holidays, this extra protection can help reduce infection and spread. The CDC now strongly recommends that individuals over 50 get a booster shot. However, those over 18, particularly those with conditions like asthma, diabetes, or obesity, are also encouraged to receive a booster for added protection.

Investing in vaccines is crucial for stopping COVID transmission and returning to normalcy. Vaccinated individuals are protected from severe illness and can resume activities without masks. However, reports show a decline in immunity over time, necessitating booster shots. The goal is to increase immunity levels to minimize infections. The effectiveness of vaccines against variants is emphasized, highlighting the importance of getting vaccinated.

Dr. Menares and an interlocutor debate the science behind pediatric COVID vaccination and routine immunizations, focusing on transmission, hospitalization, and risk. - The interlocutor asks whether the COVID vaccine prevents transmission. Speaker 1 answer: the vaccine can reduce viral load in individuals who are infected, and with reduced viral load, there is reduced transmission. The interlocutor reframes, insisting that the vaccine does not prevent transmission and notes decreasing effectiveness over time, citing Omicron data showing around 16% reduction when there is a reduction. - On hospitalization for children 18 and under: Speaker 0 asserts the vaccine does not reduce hospitalization for 18-year-olds; statistics are inconclusive due to small numbers of hospitalizations in that age group (approximately 76 million people aged 18 in the country, with 183 deaths and a few thousand hospitalizations in 2020–2021; numbers have since dropped). The argument emphasizes a need to discuss the issue. - On death for children 18 and under: Speaker 0 says the vaccine does not reduce the death rate; claims there is no statistical evidence that it reduces deaths. Speaker 1 responds with a more cautious stance: “It can,” but Speaker 0 counters, calling that an insufficient answer. - The discussion references the vaccine approval process and ongoing debates in vaccine committees. The interlocutor states that when the vaccine was approved for six months and older, the discussion acknowledged no proof of reduction in hospitalization or death. The argument asserts that the justification for vaccination is based on antibody generation rather than clear hospitalization/death data. The interlocutor contends that immunology measurements (antibody production) do not necessarily justify vaccination frequency. - The core debate centers on what the science supports for vaccinating six-month-olds and the benefits versus risks. The interlocutor argues there is no hospitalization or death benefit for vaccination in this age group, and notes a known risk of myocarditis in younger populations, estimated somewhere between six and ten per ten thousand, which the interlocutor claims is greater than the risk of hospitalization or death being measurable. - The exchange then shifts to changing the childhood vaccine schedule, particularly the hepatitis B vaccine given to newborns when the mother is not hepatitis B positive. The interlocutor asks for the medical or scientific reason to give a hepatitis B vaccine to a newborn with an uninfected mother, arguing that the discussion should focus on whether to change the schedule rather than declaring all vaccines as good or bad. - Speaker 1 says they agreed with considering the science and would not pre-commit to approving all ACIP recommendations without the science. Speaker 0 disagrees, asserting their position that the debate should center on the medical rationale for these specific vaccines and schedules, not on a blanket endorsement of vaccines. - Throughout, the dialogue emphasizes examining the medical reasons and evidence for specific vaccines and schedules, rather than broad generalizations about vaccines.

The speakers discuss the effectiveness of COVID-19 vaccines and the importance of getting vaccinated. They emphasize that vaccinated individuals are less likely to get infected, transmit the virus, or experience severe illness. They mention that vaccines slightly reduce transmission but do not completely prevent it. The speakers also mention the possibility of waning immunity over time and suggest that booster shots may be necessary. They encourage everyone to get vaccinated and highlight the goal of achieving high immunity levels to return to normalcy. The plan is for every adult to receive a booster shot.

In a study of 1,000 people in Israel, it was found that those who received two vaccine doses were 27 times more likely to get reinfected. The vaccine does not prevent infections or transmission, as seen in studies from England, Scotland, and other European countries where triple-vaccinated individuals are most likely to die. On the other hand, natural immunity from previous infections, such as SARS CoV-one, can last for 18 years and provide long-lasting and broad protection. In conclusion, natural immunity should be considered as an important factor moving forward.

The speaker discusses the safety concerns of COVID-19 vaccines and emphasizes the importance of getting vaccinated. They mention the risk of blood clots with the J&J vaccine but assure that all vaccines are good and safe. The speaker urges parents to vaccinate their children, even though COVID poses minimal threat to healthy kids. They recommend adolescents to get two doses of the vaccine and mention the possibility of needing a booster shot. The speaker suggests that innovative solutions may be required, including a fourth immunization. They highlight the importance of getting vaccinated to protect against hospitalizations and rising COVID cases. The speaker also addresses misinformation and emphasizes the need for everyone to be vaccinated, including children. They mention the possibility of needing additional boosters in the future. The transcript ends with praise for the speaker's expertise and a brief mention of monkeypox being transmitted among a specific social network.

The speaker asks if there is a higher incidence of myocarditis among adolescent males aged 16 to 24 after taking the vaccine. The other speaker responds by saying that the data from the CDC shows that there is actually less myocarditis in people who get the vaccine compared to those who get COVID. The first speaker disagrees and presents six peer-reviewed papers that contradict this claim. They also mention speaking with the president who privately acknowledged the increased risk of myocarditis. The conversation then shifts to discussing the rationality of mandating three vaccines for adolescent boys and the timing of myocarditis after the second dose. The first speaker criticizes the CDC's recommendation to vaccinate individuals who have recovered from COVID and experienced myocarditis. They argue that many countries do not offer the vaccine to children unless they are at risk for severe disease. The first speaker concludes by stating that the risk and benefits of vaccination need to be weighed, and that parents are unlikely to comply with mandatory vaccination for their children.

The speaker questions why there hasn't been research done to show that natural immunity protects against recurrent infection. They mention that studies have shown that individuals with natural immunity have antibodies, T cells, and B cells that are considered adequate for protection. The speaker also mentions that the CDC has access to patient data. However, the other speaker responds by stating that their current stance is that everyone who has been previously infected should still be vaccinated, without directly addressing the question.

The speaker asks if there is a higher incidence of myocarditis among boys aged 16 to 24 after taking the vaccine. The other speaker responds that the data from the CDC actually show that there is less risk of myocarditis for those who get the vaccine compared to those who get COVID infection. The first speaker clarifies if they are saying that males in the 16 to 24 age group who take the vaccine have a lower risk of myocarditis than those who contract the disease. The second speaker confirms this.

The speakers discuss the challenges of teaching unvaccinated students and the importance of getting vaccinated. One speaker shares their motivation, having had COVID-19 and having antibodies. They emphasize the need to get vaccinated for the sake of others, especially the vulnerable. The discussion touches on the possibility of needing three vaccine doses and potential restrictions for the unvaccinated. The speakers mention protests against government measures and the spread of misinformation. The video concludes with mention of political parties considering a vaccine mandate due to the high risk of transmission among the unvaccinated.

Getting the third vaccine dose offers protection against severe illness and reduces the risk of initial infection. However, even with two, three, or four doses, the vaccine is not very effective at preventing infections altogether. This is evident in the tens of thousands of cases reported during this wave.

The speakers discuss the need for vaccines to combat the spread of the virus. They mention that traditional vaccines require booster shots to increase protection over time, but it is uncertain if the same applies to the RNA vaccines. They mention the possibility of a fourth dose and the uncertainty surrounding the duration of immunity. They acknowledge that the situation with the virus is unique and express a tolerance for doubts and questions.

We have experience with this vaccine in a billion people, showing it is safe. While there is a low risk of myocarditis with mRNA vaccines, the risk from COVID is higher than the vaccine's risk, especially in young men.

There is concern about the safety of coronavirus vaccines, but they are still recommended. The J&J vaccine has a risk of blood clots. Vaccinating children is important, even though COVID poses little threat to them. Boosters are now being recommended, with the possibility of needing more in the future. Disinformation campaigns have hindered progress. It is crucial to get vaccinated and combat fake information. Doctor Peter Hotez is seen as an expert on the topic. Monkeypox is a concern among men who have sex with men. Overall, the focus is on vaccination to overcome the pandemic.

Vaccinated individuals are protected against COVID-19 and its variants, as the vaccines are highly effective. They do not carry the virus, get sick, or transmit it to others. Vaccination allows society to return to normal by reducing transmission. Getting both vaccine shots is crucial. Vaccinated people are safe from hospitalization, ICU stays, and death, and they no longer need to wear masks. However, they cannot prevent transmission. Israel's experience suggests a waning of immunity, indicating the need for booster shots. The plan is for every adult to receive a booster shot. Overall, vaccines have been a highly successful investment.

The dialogue centers on the FDA’s decision to limit access to COVID-19 boosters to people 65 and older or those at high risk, and the rationale behind that stance. The first speaker notes surprise at the FDA announcement, which they interpret as restricting individual choice by narrowing booster eligibility. They ask for clarification on why the decision was made and why boosters might no longer be available to those who believe they would help. The second speaker explains there has been no randomized controlled trial for four to five years, so the appropriate number of boosters for a healthy American is unknown. They pose questions: should booster frequency be like the two-dose pattern of the MMR vaccine, like the two or three doses for HPV or hepatitis B, or could it be as high as 80 boosters over a healthy person’s lifespan? They state that the theory of a repeated booster strategy for healthy individuals lacks supporting data. Their job, they say, is to require clinical trial data before approving a COVID vaccine for younger, healthy Americans, noting this population differs from five years ago due to ubiquitous population-based immunity, a different circulating virus, and a vaccine formulation that introduces a new protein in the body. They ask whether it makes sense to “blindly rubber stamp” a vaccine that creates a new protein every year for the rest of a person’s life, implying skepticism about perpetual annual vaccination for the next century. Consequently, they published a framework in The New England Journal of Medicine for “sensible COVID vaccine booster regulation in The United States” that uses an age-stratified approach and positions the U.S. as “catching up with the rest of the world.” They claim part of the motivation is alignment with international practices: the UK recommends boosters for those 60, 75 and high risk, and France for 80 and high risk. They argue against pushing boosters on healthy six-year-old girls annually without evidence. They reference the framework’s reception from vaccine manufacturers, noting they issued positive statements because they like predictability.

Consider speaking to your healthcare provider for more clarity. Currently, we take a risk-based approach to vaccination. The risk of hospitalization for a healthy 18-year-old without underlying medical conditions is very low. There is a small risk of myocarditis, about 1 in 5,000, which should be weighed against the benefits of vaccination. Opening up vaccination to all adults is a decision I agree with, but it's important to understand the nuances. People with underlying illnesses should definitely get vaccinated, while others may consider it based on personal circumstances. It's also important to note that vaccination should not affect eligibility for future doses. Although the risk of myocarditis decreases with subsequent doses, it is still a concern for young, healthy males. Individual discussions are necessary.

Initially, all vaccines released under emergency use authorization by the FDA were considered outstanding. The J&J vaccine carries a risk of life-threatening blood clots. Despite claims that COVID poses zero threat to healthy children, vaccination for children was urged. Two mRNA vaccines were considered a three-dose vaccine. Two doses were found to be insufficient for emergency room visits and hospitalizations, necessitating a third immunization. A fourth immunization was suggested as a potential innovative solution. The numbers are trending up again, so a new bivalent booster is recommended for everyone ages 12 and older. Those over 50 who have had two boosters more than 2-4 months prior may need a third booster, a fifth immunization. Boosters may not be holding up as well as desired, potentially requiring boosters every few months. Disinformation campaigns have promoted fake concepts of herd immunity and discredited masks. Vaccinating is considered our last hope. The single most impactful thing is to be fully boosted, preferably twice boosted. Monkeypox is accelerating among men who have sex with men, though sources disagree on whether it is sexually transmitted.

Speaker 0 advises getting the shot, but it's optional. Speaker 1 agrees to get it and wear a mask. Speaker 0 plans to get the shot but won't wear a mask. Speaker 2 is surprised and asks how many shots Speaker 0 has had. Speaker 0 mentions having had six shots so far and will soon get the seventh. They also mention having had COVID three times.

Vaccinated individuals are protected against COVID-19 and its variants, as the vaccines are highly effective. They do not carry the virus, get sick, or transmit it to others. Vaccination allows society to return to normal. Fully vaccinated people no longer need to wear masks or practice physical distancing, and they are unlikely to be hospitalized or die from the virus. However, vaccines only slightly reduce transmission, and there is a need for new vaccination strategies. Reports from Israel suggest a waning of immunity, indicating the importance of booster shots. The plan is for every adult to receive a booster shot.

A communication problem arose when it was intimated that vaccines would protect against getting COVID altogether, which wasn't supported by evidence. Vaccines protect against illness in the lower respiratory system, but the virus could still be carried in the upper airway and potentially spread. This led to distrust of mRNA vaccines, as people who got COVID after vaccination questioned the vaccine's effectiveness. Recent data shows that vaccines work well in preventing illness and infection, and make it unlikely that someone would pass the infection to someone else. The concern was that vaccinated people could be unwitting carriers, but recent data suggests this is very unlikely. Vaccinated people not wearing masks are not doing a disservice to their community. Unvaccinated people could be putting other unvaccinated people at risk. Institutions may require proof of vaccination, which will be a tough call.